These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 14705182)

  • 1. High-throughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism.
    Ansede JH; Thakker DR
    J Pharm Sci; 2004 Feb; 93(2):239-55. PubMed ID: 14705182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries.
    Jenkins KM; Angeles R; Quintos MT; Xu R; Kassel DB; Rourick RA
    J Pharm Biomed Anal; 2004 Mar; 34(5):989-1004. PubMed ID: 15019033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic vivid p450 substrate.
    Marks BD; Smith RW; Braun HA; Goossens TA; Christenson M; Ozers MS; Lebakken CS; Trubetskoy OV
    Assay Drug Dev Technol; 2002 Nov; 1(1 Pt 1):73-81. PubMed ID: 15090158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro ADME profiling using high-throughput rapidfire mass spectrometry: cytochrome p450 inhibition and metabolic stability assays.
    Wu X; Wang J; Tan L; Bui J; Gjerstad E; McMillan K; Zhang W
    J Biomol Screen; 2012 Jul; 17(6):761-72. PubMed ID: 22460176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates.
    Di L; Kerns EH; Hong Y; Kleintop TA; McConnell OJ; Huryn DM
    J Biomol Screen; 2003 Aug; 8(4):453-62. PubMed ID: 14567798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput mass spectrometric cytochrome P450 inhibition screening.
    Lim KB; Ozbal CC; Kassel DB
    Methods Mol Biol; 2013; 987():25-50. PubMed ID: 23475665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico prediction of cytochrome P450-mediated drug metabolism.
    Zhang T; Chen Q; Li L; Liu LA; Wei DQ
    Comb Chem High Throughput Screen; 2011 Jun; 14(5):388-95. PubMed ID: 21470181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of a cocktail approach to screen cytochrome P450 BM3 libraries for metabolic activity and diversity.
    Reinen J; Postma G; Tump C; Bloemberg T; Engel J; Vermeulen NP; Commandeur JN; Honing M
    Anal Bioanal Chem; 2016 Feb; 408(5):1425-43. PubMed ID: 26753974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput cytochrome p450 inhibition assays by ultrafast gradient liquid chromatography with tandem mass spectrometry using monolithic columns.
    Peng SX; Barbone AG; Ritchie DM
    Rapid Commun Mass Spectrom; 2003; 17(6):509-18. PubMed ID: 12621611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of 1-aminobenzotriazole in differentiating the role of CYP-mediated first pass metabolism and absorption in limiting drug oral bioavailability: a case study.
    El-Kattan AF; Poe J; Buchholz L; Thomas HV; Brodfuehrer J; Clark A
    Drug Metab Lett; 2008 Apr; 2(2):120-4. PubMed ID: 19356080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient screening of cytochrome P450 BM3 mutants for their metabolic activity and diversity toward a wide set of drug-like molecules in chemical space.
    Reinen J; van Leeuwen JS; Li Y; Sun L; Grootenhuis PD; Decker CJ; Saunders J; Vermeulen NP; Commandeur JN
    Drug Metab Dispos; 2011 Sep; 39(9):1568-76. PubMed ID: 21673132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A high-throughput method for enzyme kinetic studies.
    Saraswat LD; Caserta KA; Laws K; Wei D; Jones SS; Adedoyin A
    J Biomol Screen; 2003 Oct; 8(5):544-54. PubMed ID: 14567781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of cytochrome p450 enzyme inhibition and inactivation in drug discovery and development.
    Nettleton DO; Einolf HJ
    Curr Top Med Chem; 2011; 11(4):382-403. PubMed ID: 21320066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of CYP-mediated drug interactions in vivo using in vitro data.
    Foti RS; Wahlstrom JL
    IDrugs; 2008 Dec; 11(12):900-5. PubMed ID: 19051152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A high-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry.
    Qin CZ; Ren X; Tan ZR; Chen Y; Yin JY; Yu J; Qu J; Zhou HH; Liu ZQ
    Biomed Chromatogr; 2014 Feb; 28(2):197-203. PubMed ID: 23946123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of cytochrome-P450 inhibition (CYP) in drug discovery: a medicinal chemistry perspective.
    Kumar S; Sharma R; Roychowdhury A
    Curr Med Chem; 2012; 19(21):3605-21. PubMed ID: 22680629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug metabolism and pharmacokinetics in drug discovery.
    Roberts SA
    Curr Opin Drug Discov Devel; 2003 Jan; 6(1):66-80. PubMed ID: 12613278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.
    Yan Z; Caldwell GW
    Curr Top Med Chem; 2001 Nov; 1(5):403-25. PubMed ID: 11899105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of mass spectrometry for in-vitro ADME assays.
    Chu I; Nomeir AA
    Curr Drug Metab; 2006 Jun; 7(5):467-77. PubMed ID: 16787156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lead optimization strategies as part of a drug metabolism environment.
    Korfmacher WA
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):481-5. PubMed ID: 12951811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.